Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioMarin Pharmaceutical
Biotech
Ascendis' dwarfism drug hits in phase 3, threatens BioMarin
Ascendis reported phase 3 growth disorder data that exceeded analyst expectations and positions the biotech to file for approval next year.
Nick Paul Taylor
Sep 17, 2024 9:36am
BioMarin builds exec team with biotech vets—Chutes & Ladders
Aug 23, 2024 8:30am
BioMarin hires Sabry and Friberg for new-look R&D, deal teams
Aug 21, 2024 9:21am
BioMarin halts preclinical gene therapy for heart condition
Aug 6, 2024 9:01am
BioMarin sheds 170 jobs in wake of narrowed R&D refocus
May 15, 2024 7:13am
BioMarin axes 4 candidates, centers R&D around 3 assets
Apr 25, 2024 10:10am